Statistiche di base
| LEI | 549300DL466NY5J6U724 |
| CIK | 1635088 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Roivant Sciences Ltd.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| May 20, 2026 |
Jurisdiction of Incorporation or Formation Company Jurisdiction of Incorporation or Formation Covant Therapeutics Operating, Inc. |
|
| May 20, 2026 |
Exhibit 99.1 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update •IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the |
|
| May 20, 2026 |
As filed with the Securities and Exchange Commission on May 20, 2026 As filed with the Securities and Exchange Commission on May 20, 2026 Registration No. |
|
| May 20, 2026 |
CALCULATION OF FILING FEE TABLES Roivant Sciences Ltd. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Roivant Sciences Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common shares, par value $0.0000000341740141 per share, reserved for issuance under the Roiv |
|
| May 20, 2026 |
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 31, 2026, Roivant Sciences Ltd. |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40782 ROIVANT SCIENCES |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2026 Roivant Sciences Ltd. |
|
| April 2, 2026 |
Exhibit 99.1 Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) • Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2026 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission File |
|
| March 23, 2026 |
EXECUTION COPY Exhibit 10.1 SETTLEMENT AGREEMENT This Settlement Agreement (“Agreement”) is entered into as of March 3, 2026 (the “Effective Date”) by and between, on the one hand, Genevant Sciences GmbH ( “Genevant”), a limited liability company organized under the laws of Switzerland having a principal place of business at Viaduktstrasse 8, 4051 Basel, Switzerland, and Arbutus Biopharma Corp. (“ |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2026 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporati |
|
| March 3, 2026 |
Exhibit 99.1 Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna • Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal • If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the |
|
| March 3, 2026 |
Exhibit 99.1 Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis • FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 • Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositis • If ap |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2026 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission File |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2026 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission File |
|
| February 6, 2026 |
Exhibit 99.1 Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 •Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 p<0.0001). Brepocitinib dem |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2026 Roivant Sciences Ltd. |
|
| December 11, 2025 |
Exhibit 99.1 Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day • Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years • Highlighting clinical execution, Roivant announces positive updates to timing guidance across four |
|
| December 11, 2025 |
Exhibit 99.2 December 11, 2025 New York City Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements reg |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2025 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. |
|
| November 10, 2025 |
Exhibit 99.1 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, November 10, 2025 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. • Brepocitinib 30 mg demonstrated clinically meaningful and statistica |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2025 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission |
|
| October 9, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 Roivant Sciences Ltd. 001-40782 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB 441-295-5950 Venker Eric Officer Common Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111 104940 1710040.33 682881743 10/09/2025 NASDAQ Common Shares 10/09/2025 Options Exercise - Grant Date 03/26/2020 Roivant Sciences Ltd. N 104940 10/09/2025 Wire N Eric Venker |
|
| October 8, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 Roivant Sciences Ltd. 001-40782 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB 441-295-5950 Venker Eric Officer Common Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111 138602 2244797.15 682881743 10/08/2025 NASDAQ Common Shares 10/08/2025 Options Exercise - Grant Date 03/26/2020 Roivant Sciences Ltd. N 10307 10/08/2025 Wire Common 10/08/20 |
|
| October 7, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 Roivant Sciences Ltd. 001-40782 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB 441-295-5950 Venker Eric Officer Common Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111 355161 5734289.35 682881743 10/07/2025 NASDAQ Common Shares 10/07/2025 Options Exercise - Grant Date 03/26/2020 Roivant Sciences Ltd. N 67171 10/07/2025 Wire Common 10/07/20 |
|
| October 6, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 Roivant Sciences Ltd. 001-40782 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB 441-295-5950 Venker Eric Officer Common Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111 171396 2800364.71 682881743 10/06/2025 NASDAQ Common Shares 10/06/2025 Options Exercise - Grant Date 03/26/2020 Roivant Sciences Ltd. N 127355 10/06/2025 Wire Common 10/06/2 |
|
| October 3, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-3 Roivant Sciences Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form |
|
| October 3, 2025 |
As filed with the Securities and Exchange Commission on October 3, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 3, 2025 Registration No. |
|
| September 23, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 Roivant Sciences Ltd. 001-40782 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB 441-295-5950 Venker Eric Officer Common Stock Charles Schwab & Co 3000 Schwab Way Westlake TX 76262 611079 9129520.26 682881743 09/23/2025 NASDAQ GS Common Stock 01/20/2023 Equity Compensation Issuer N 611079 01/20/2023 Services Rendered N Eric Venker 7TH FLOOR, 50 BROADWAY LONDON X0 S |
|
| September 22, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 ROIVANT SCIENCES LTD. 001-40782 7th Floor 50 Broadway London X0 SW1H 0DB 44 207 400 3347 ERIC VENKER Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 316182 4741054.24 682881743 09/22/2025 NASDAQ Common 09/22/2025 Stock Option Exercise Issuer N 316182 09/22/2025 Cash N ERIC VENKER 7th Fl |
|
| September 22, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 Roivant Sciences Ltd. 001-40782 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB 441-295-5950 Venker Eric Officer Common Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111 100000 1501338.85 682881743 09/22/2025 NASDAQ Common Shares 09/22/2025 Options Exercise - Grant Date 4/20/2022 Roivant Sciences Ltd. N 100000 09/22/2025 Wire N Eric Venker c |
|
| September 19, 2025 |
144 0001801917 XXXXXXXX LIVE 0001635088 ROIVANT SCIENCES LTD. 001-40782 7th Floor 50 Broadway London X0 SW1H 0DB 44 207 400 3347 ERIC VENKER Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 683818 10220412.21 682881743 09/19/2025 NASDAQ Common 09/19/2025 Stock Option Exercise Issuer N 683818 09/19/2025 Cash N ERIC VENKER 7th F |
|
| September 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2025 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission |
|
| September 17, 2025 |
Exhibit 99.1 Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) • Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscle |
|
| September 17, 2025 |
Brepocitinib in DM: VALOR Topline Results September 17, 2025 Exhibit 99.2 Brepocitinib in DM: VALOR Topline Results September 17, 2025 2 For investor audiences only Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical fac |
|
| September 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 10, 2025 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission |
|
| September 3, 2025 |
Exhibit 99.2 Targeted science, Tailored solutions for people with autoimmune disease Batoclimab Graves’ Disease Proof-of-Concept Study Remission Data September 2025 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of wo |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2025 Roivant Sciences Ltd. (Exact name of registrant as specified in its charter) Bermuda 001-40782 98-1173944 (State or other jurisdiction of incorporation) (Commission |
|
| September 3, 2025 |
Exhibit 99.1 Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients • First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients • Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroi |
|
| August 11, 2025 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of July 28, 2025, by and between Eric Venker (the “Executive”) and IMVT Corporation (the “Company”). Reference is made to that certain Amended and Restated Executive Employment Agreement entered into by and between the Executive and Roivant Sciences, Inc. (“RSI”), an affiliate of the Company, dated as |
|
| August 11, 2025 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of July 28, 2025, by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Eric Venker, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”). Reference is made to that certain Employment |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2025 Roivant Sciences Ltd. |
|
| August 11, 2025 |
IMMUNOVANT, INC. 2019 EQUITY INCENTIVE PLAN CAPPED VALUE APPRECIATION RIGHT AWARD GRANT NOTICE Exhibit 10.4 IMMUNOVANT, INC. 2019 EQUITY INCENTIVE PLAN CAPPED VALUE APPRECIATION RIGHT AWARD GRANT NOTICE Participant: [NAME] (the “Participant”) Company: Immunovant, Inc., a Delaware corporation (the “Company”) Plan: Immunovant, Inc. 2019 Equity Incentive Plan (as amended, the “Plan”) Notice: The Participant has been granted an award of Capped Value Appreciation Rights (“CVARs”) in accordance w |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registr |
|
| August 11, 2025 |
Exhibit 10.7 Special Equity Award Opportunity Letter Eric Venker President and Chief Operating Officer July 26, 2024 Dear Eric, As a key employee of Roivant Sciences, Inc. (“Roivant”), we consider you integral to the future success of our business. Accordingly, we are pleased to provide you with the potential opportunity to receive one or more special grants of performance-based restricted stock u |
|
| August 11, 2025 |
Roivant Sciences, Inc.• 151 W. 42nd Street, 15th Floor, New York, NY 10036 Exhibit 10.1 02/07/2025 Dear Jenni, Welcome to Roivant Sciences, Inc. (Roivant), where we build and launch healthcare companies in biotechnology and life sciences. Roivant is focused on value creation, and our people are our most valuable asset. We believe that you will make significant contributions to Roivant’s growth and success, and are excited to extend this employment offer based on the term |
|
| August 11, 2025 |
Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, August 11, 2025 – Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. • Brepocitinib VALOR Phase 3 study in dermatomyositis (DM) remains on track for topl |
|
| July 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 29, 2025 |
Annual Report 2024Dear Shareholders, From a distance, this past year may have looked like a relatively quiet one, with fewer dramatic pipeline shifts and headline-making deals for us versus 2023. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| June 25, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2025 Roivant Sciences Ltd. |
|
| May 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2025 Roivant Sciences Ltd. |
|
| May 29, 2025 |
Exhibit 10.38 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of the March 16, 2025, by and between Roivant Sciences, Inc. (the “Company”), a Delaware corporation, having a place of business at 151 West 42nd Street, 15th Floor, New York, NY 10036, and Rakhi Kumar (“Consultant”), an individual, with domicile in New Jersey. WITNESSETH: WHEREAS, reference |
|
| May 29, 2025 |
ROIVANT SCIENCES LTD. INSIDER TRADING POLICY Effective as of May 28, 2025 Exhibit 19 ROIVANT SCIENCES LTD. INSIDER TRADING POLICY Effective as of May 28, 2025 1. Introduction This Insider Trading Policy (this “Policy”) determines acceptable transactions in the securities of Roivant Sciences Ltd. (“Roivant”) by directors, executive officers and employees (collectively, “personnel”) of Roivant and its controlled affiliates (each, a “Controlled Affiliate” and, together wit |
|
| May 29, 2025 |
One-Time Retentive Cash Award Statement Exhibit 10.35 One-Time Retentive Cash Award Statement [NAME] [TITLE] Dear [NAME], In recognition of your hard work and dedication and in anticipation of your future contributions to Roivant and the Vants, we are pleased to provide you with the following long-term cash incentive award (“Cash Award”). Total Award: $[X] Cash Award Payment Dates1 2 To be paid prior to [Date] $ [50%] To be paid on Sept |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40782 ROIVANT SCIENCES |
|
| May 29, 2025 |
Roivant Sciences, Inc. • 151 West 42nd Street, 15th Floor, New York, NY 10036 • roivant.com Exhibit 10.37 February 14, 2025 Rakhi Kumar [...] RE: Separation Agreement and General Release Dear Rakhi, Your employment with Roivant Sciences, Inc. will be terminated effective March 16, 2025 (the “Separation Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which Roivant Sciences, Inc. is offering you additional pay and benefits |
|
| May 29, 2025 |
Exhibit 99.1 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 – Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, and provided a business update. • Brepocitinib program progressing well with rapid |
|
| May 29, 2025 |
List of Subsidiaries of Roivant Sciences Ltd. Exhibit 21.1 List of Subsidiaries of Roivant Sciences Ltd. * The names of certain other subsidiaries of Roivant Sciences Ltd. are omitted because, considered in the aggregate, they would not constitute a “significant subsidiary.” Company Jurisdiction of Incorporation or Formation Covant Therapeutics Operating, Inc. United States – Delaware Genevant Sciences BioVentures GmbH Switzerland Genevant Sc |
|
| May 29, 2025 |
Exhibit 10.36 Roivant Sciences Ltd. Performance Restricted Stock Unit Award Grant Notice (2021 Equity Incentive Plan) Roivant Sciences Ltd. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the Participant a Performance Restricted Stock Unit Award (the “PSU Award”) of the number of Performance Restricted Stock Units (each a “PSU” and, together, the “PSUs”) |
|
| May 29, 2025 |
Exhibit 10.34 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Retention Award Agreement Mayukh Sukhatme President and Chief Investment Officer July 26, 2024 Dear Mayukh, |
|
| April 21, 2025 |
Exhibit 99.1 Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 • Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant • Pete Salzmann, M.D. retired from his role as |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2025 Roivant Sciences Ltd. |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2025 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 19, 2025 |
Exhibit 99.1 Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies • Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (wi |
|
| March 19, 2025 |
Exhibit 99.2 Targeted science, Tailored solutionsfor people with autoimmune disease MG & CIDP Results March 2025 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 25, 2025 |
Principal Business Address of Employer Exhibit 99.1 Covered Persons Roivant has a board of directors (such individuals, collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Address of Employer Present Principal Occupation C |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 18, 2025 |
Principal Business Address of Employer Exhibit 99.1 Covered Persons Roivant has a board of directors and executive officers (such individuals, collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Address of Employer Present |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Reg |
|
| February 10, 2025 |
EX-99.1 2 ef20043151ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update BASEL, LONDON and NEW YORK, February 10, 2025 – Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. • Brepocitinib to be developed in third indica |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2025 Roivant Sciences Ltd. |
|
| January 15, 2025 |
Exhibit 7.01 Schedule A Covered Persons Roivant has a board of directors (such members of the board of directors collectively, the "Covered Persons"). The name, present principal occupation and country of citizenship of each of the Covered Persons is set forth below, along with the principal business address of the employer of each of the Covered Persons. Name Principal Business Address of Employe |
|
| December 3, 2024 |
Exhibit 99.1 Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis • Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis • Further development of namilumab for the treatment of sarcoidosis will be discontinued BASEL, Switzerland and LONDON and NEW YORK, December 3, 2024 GLOBE NEWSWIRE) – Kinevant Science |
|
| December 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 14, 2024 |
ROIV / Roivant Sciences Ltd. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2411143013ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Roivant Sciences Ltd. (Name of Issuer) Common Shares, $0.0000000341740141 par value per share ( |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Re |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 Roivant Sciences Ltd. |
|
| November 12, 2024 |
Exhibit 10.46 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT TO THE LICENSE AGREEMENT DATED JULY 27, 2023 THIS AMENDMENT (the “Amendment”), effective as of t |
|
| November 12, 2024 |
ROIV / Roivant Sciences Ltd. / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ROIVANT SCIENCES LTD COMMON STOCK Cusip #G76279101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G76279101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 49,134,410 Item 6: 0 Item 7: 49,145,056 Item 8: 0 Item 9 |
|
| November 12, 2024 |
Exhibit 10.45 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the “Agreement”), effective as of the date of the last signature |
|
| November 12, 2024 |
ROIV / Roivant Sciences Ltd. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GRoivantSci.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Roivant Sciences Ltd (Title of Class of Secu |
|
| November 12, 2024 |
Exhibit 99.1 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, November 12, 2024 – Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. • Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infe |
|
| November 8, 2024 |
ROIV / Roivant Sciences Ltd. / BlackRock, Inc. Passive Investment SC 13G 1 bmg762791017110824.txt bmg762791017110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ROIVANT SCIENCES LTD - (Name of Issuer) Common Stock - (Title of Class of Securities) BMW4NZ9 - (SEDOL Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 4, 2024 |
ROIV / Roivant Sciences Ltd. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GRoivantSci.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Roivant Sciences Ltd (Title of Class of Secur |
|
| October 28, 2024 |
Exhibit 99.1 Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. BASEL, Switzerland and LONDON and NEW YORK, October 28, 2024 (GLOBE NEWSWIRE) – Organon (NYSE: OGN), a global healthcare company with a mission to i |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2024 Roivant Sciences Ltd. |
|
| October 24, 2024 |
ROIV / Roivant Sciences Ltd. / BlackRock, Inc. Passive Investment SC 13G 1 bmg762791017102424.txt bmg762791017102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ROIVANT SCIENCES LTD - (Name of Issuer) Common Stock - (Title of Class of Securities) BMW4NZ9 - (SEDOL Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2024 Roivant Sciences Ltd. |
|
| September 23, 2024 |
Exhibit 2.1 CERTAIN INFORMATION HAS BEEN REDACTED FROM HIS EXHIBIT IN ACCORDANCE WITH ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE SUCH INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT HAS BEEN SO REDACTED FROM THIS EXHIBIT HAS BEEN MARKED WITH “[***]” TO INDICATE THE OMISSION. EXECUTION VERSION AGREEMENT AND PL |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2024 Roivant Sciences Ltd. |
|
| September 18, 2024 |
Exhibit 99.2 September 2024 Dermavant Announces $1.2BN Deal with Organon 2 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presenta |
|
| September 18, 2024 |
Exhibit 99.1 Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon’s international dermatology capabilities to the U.S. BASEL |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 10, 2024 |
Exhibit 99.1 Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator • Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for pulmonary hypertension as |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 9, 2024 |
Roivant Provides Update on Graves’ Disease Development Program Exhibit 99.1 Roivant Provides Update on Graves’ Disease Development Program • High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12 • High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs at week 12 • Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential best-in |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2024 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 10.40 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXECUTION VERSION FIRST AMENDMENT TO CREDIT AGREEMENT This First Amendment to Credit Agreement (this “Amen |
|
| August 9, 2024 |
Employment Agreement between Roivant Sciences, Inc. and Rakhi Kumar, dated as of June 5, 2023 Exhibit 10.44 EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of June 5, 2023 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “ Company”), and Rakhi Kumar, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”). RECITALS WHEREAS, the Compa |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registr |
|
| August 9, 2024 |
SECOND AMENDMENT TO FUNDING AGREEMENT Exhibit 10.41 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXECUTION VERSION SECOND AMENDMENT TO FUNDING AGREEMENT This Second Amendment to Funding Agreement (this “ |
|
| August 9, 2024 |
FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AND SALE AGREEMENT Exhibit 10.42 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXECUTION VERSION FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AND SALE AGREEMENT This First Amendment to |
|
| August 9, 2024 |
Employment Agreement between Roivant Sciences, Inc. and Richard Pulik, dated as of August 31, 2021 Exhibit 10.43 EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of August 31, 2021, by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Richard Pulik, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”). RECITALS WHEREAS, the Compan |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 Roivant Sciences Ltd. |
|
| August 8, 2024 |
Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, August 8, 2024 – Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2024, and provided a business update. • Immunovant completed enrollment in batoclimab pivotal myasthenia gravis (MG) trial; |
|
| July 26, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) ROIVANT SCIENCES LTD. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2)(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Common shares, par value |
|
| July 26, 2024 |
2023 Annual ReportDear Roivant Shareholders, Ten years ago, Roivant was founded on the premise that inefficiencies in the biopharma industry can potentially lead to substantial return on investment through approaching drug development with the same principles with which a value investor approaches investing. |
|
| July 26, 2024 |
DEF 14A 1 ny20026685x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024 As filed with the Securities and Exchange Commission on July 26, 2024 Registration No. |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| May 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2024 Roivant Sciences Ltd. |
|
| May 30, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Roivant Sciences Ltd. (Exact name of Registrant as Specified in Its Charter) Bermuda 001-40782 98-1173944 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2024 |
Exhibit 99.1 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 – Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. • Once-daily brepocitinib produced the best Treatme |
|
| May 30, 2024 |
List of Subsidiaries of Roivant Sciences Ltd. EXHIBIT 21.1 List of Subsidiaries of Roivant Sciences Ltd. * The names of certain other subsidiaries of Roivant Sciences Ltd. are omitted because, considered in the aggregate, they would not constitute a “significant subsidiary.” Company Jurisdiction of Incorporation or Formation Covant Therapeutics Operating, Inc. United States – Delaware Dermavant Sciences GmbH Switzerland Dermavant Sciences Ltd |
|
| May 30, 2024 |
Roivant Sciences Ltd. Compensation Recoupment Policy Exhibit 97 ROIVANT SCIENCES LTD. COMPENSATION RECOUPMENT POLICY This Roivant Sciences Ltd. Compensation Recoupment Policy (“Policy”) has been adopted by the Compensation Committee of the Board of Directors (the “Board”) of Roivant Sciences Ltd. (the “Company”) on September 12, 2023. This Policy provides for the recoupment of erroneously awarded compensation in the event of a financial restatement |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40782 ROIVANT SCIENCES |
|
| April 2, 2024 |
ROIV / Roivant Sciences Ltd. / Sumitomo Chemical Co., Ltd. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Roivant Sciences Ltd. (Name of Issuer) Common Shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) April 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| April 2, 2024 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares, par value $0.0000000341740141 per share, of Roivant Sciences Ltd. (this “Agreement”), is being filed, and all ame |
|
| April 2, 2024 |
Exhibit 99.1 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million • Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2024 Roivant Sciences Ltd. |
|
| March 7, 2024 |
ROIV / Roivant Sciences Ltd. / QVT Financial LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Roivant Sciences Ltd. (Name of Issuer) Common shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) March 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
ROIV / Roivant Sciences Ltd. / Ramaswamy Vivek Passive Investment SC 13G/A 1 eps11181.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Roivant Sciences Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) G76279 101 (CUSIP Number) 12/31/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 14, 2024 |
ROIV / Roivant Sciences Ltd. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402141813ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Roivant Sciences Ltd. (Name of Issuer) Common shares, $0.0000000341740141 par value per share ( |
|
| February 14, 2024 |
ROIV / Roivant Sciences Ltd. / Dexcel Pharma Technologies Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm246088d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Roivant Sciences Ltd. (Name of Issuer) Common shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this |
|
| February 14, 2024 |
ROIV / Roivant Sciences Ltd. / QVT Financial LP - SC 13G/A Passive Investment SC 13G/A 1 d790270dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Roivant Sciences Ltd. (Name of Issuer) Common shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this S |
|
| February 13, 2024 |
ROIV / Roivant Sciences Ltd. / Ramaswamy Vivek Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Roivant Sciences Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) G76279 101 (CUSIP Number) 12/31/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Ru |
|
| February 13, 2024 |
Exhibit 99.1 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update BASEL, LONDON, and NEW YORK, February 13, 2024 – Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. • Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in c |
|
| February 13, 2024 |
ROIV / Roivant Sciences Ltd. / SB INVESTMENT ADVISERS (UK) LTD Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Roivant Sciences Ltd. (Name of Issuer) Common Shares (Title of Class of S |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Reg |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2024 Roivant Sciences Ltd. |
|
| February 1, 2024 |
ROIV / Roivant Sciences Ltd. / Sumitomo Chemical Co., Ltd. - SC 13G/A Passive Investment SC 13G/A 1 d724028dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Roivant Sciences Ltd. (Name of Issuer) Common Shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Sta |
|
| February 1, 2024 |
EX-99.1 2 d724028dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares, par value $0.0000000341740141 per share, of Roivant Sciences Ltd. (this “Agreement”), |
|
| December 20, 2023 |
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease Exhibit 99.1 Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease NEW YORK, December 20, 2023 – Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patien |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2023 Roivant Sciences Ltd. |
|
| December 20, 2023 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On December 14, 2023, Roivant Sciences Ltd. (“Roivant” or the “Company”) completed the previously announced sale (the “Transaction”) of all of the shares of capital stock it held in Telavant Holdings, Inc. (“Telavant”) to Roche Holdings, Inc. (“Roche” or the “Buyer”). The Transaction was made pursuant to a Stock Purchase |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2023 Roivant Sciences Ltd. |
|
| December 14, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2023 Roivant Sciences Ltd. |
|
| December 14, 2023 |
Exhibit 99.1 Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease BASEL, Switzerland and LONDON and NEW YORK, December 14, 2023 (GLOBE NEWSWIRE) - Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, |
|
| November 28, 2023 |
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential Exhibit 99.1 Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential • Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402 • IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 study • IMVT-1402 600 mg was observed to d |
|
| November 28, 2023 |
Exhibit 99.2 Targeted science, Tailored solutionsfor people with autoimmune disease Portfolio Update November 28, 2023 Forward-Looking Statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “ |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 28, 2023 Roivant Sciences Ltd. |
|
| November 27, 2023 |
Exhibit 99.1 Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus • Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52 • Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable s |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 Roivant Sciences Ltd. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Roivant Sciences Ltd. |
|
| November 13, 2023 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXECUTION VERSION STOCK PURCHASE AGREEMENT BY AND AMONG ROCHE HOLDINGS, INC., ROIVANT SCIENCES LTD., PFIZER |
|
| November 13, 2023 |
Exhibit 99.1 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update • Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitis • IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Re |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 22, 2023 Roivant Sciences Ltd. |
|
| October 23, 2023 |
Exhibit 99.1 Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant ● Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases ● RVT-3101 is a P |
|
| October 6, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-274804 PROSPECTUS Up to $1,500,000,000 Common Shares Preference Shares Debt Securities Warrants Units From time to time, we may offer and sell up to an aggregate amount of $1.5 billion of any combination of the securities described in this prospectus, either individually or in combination, at prices and on terms described in |
|
| October 4, 2023 |
ROIVANT SCIENCES LTD. 7th Floor 50 Broadway London SW1H 0DB United Kingdom ROIVANT SCIENCES LTD. 7th Floor 50 Broadway London SW1H 0DB United Kingdom October 4, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren S. Hamill Re: Roivant Sciences Ltd. Registration Statement on Form S-3 File No. 333-274804 Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| October 4, 2023 |
United States securities and exchange commission logo October 4, 2023 Matt Maisak Chief Operating Officer Roivant Sciences Ltd. |
|
| October 4, 2023 |
IMVT / Immunovant Inc / Roivant Sciences Ltd. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7)* Under the Securities Exchange Act of 1934 Immunovant, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45258J 102 (CUSIP Number) 7th Floor 50 Broadway London SW1H 0DB United Kingdom +44 207 400 3347 With copies to: Derek J. Dostal Stephen A. Byeff Da |
|
| September 29, 2023 |
FORM OF COMMON SHARE PURCHASE AND SALE AGREEMENT Exhibit 1.1 Certain identified information has been excluded from this exhibit pursuant to Item 601(b)(10) of Regulation S-K because it is both not material and is the type of information that the Registrant treats as confidential. Information that was omitted has been noted with a placeholder identified by the mark “[***]” September 26, 2023 FORM OF COMMON SHARE PURCHASE AND SALE AGREEMENT Roivan |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ROIVANT SCIENCES LTD. |
|
| September 29, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2023 Roivant Sciences Ltd. |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 29, 2023 Registration No. |
|
| September 26, 2023 |
Exhibit 99.2 Targeted science, Tailored solutionsfor people with autoimmune disease IMVT-1402 Initial First-in-human Data Presentation September 26, 2023 Forward-Looking Statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such |
|
| September 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2023 Roivant Sciences Ltd. |
|
| September 26, 2023 |
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results Exhibit 99.1 Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results • IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab • No decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 week |
|
| September 26, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267503 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED OCTOBER 3, 2022) 19,600,685 Common Shares ROIVANT SCIENCES LTD. We are offering 19,600,685 common shares in this offering. Our common shares are listed on the Nasdaq Global Market under the trading symbol “ROIV.” On September 25, 2023, the last reported sale price of our comm |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2023 Roivant Sciences Ltd. |
|
| September 11, 2023 |
Roivant Announces Completion of Redemption of its Outstanding Warrants Exhibit 99.1 Roivant Announces Completion of Redemption of its Outstanding Warrants BASEL, Switzerland and LONDON and NEW YORK, September 11, 2023 (GLOBE NEWSWIRE) – Roivant (Nasdaq: ROIV) today announced that it completed the redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2023 Roivant Sciences Ltd. |
|
| August 17, 2023 |
Exhibit 99.1 Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants BASEL, Switzerland and LONDON and NEW YORK, August 17, 2023 (GLOBE NEWSWIRE) – Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and |
|
| August 17, 2023 |
Exhibit 99.2 August 17, 2023 NOTICE OF REDEMPTION FAIR MARKET VALUE TO HOLDERS OF ROIVANT SCIENCES LTD.’S PUBLIC WARRANTS (CUSIP G76279119) AND PRIVATE WARRANTS (CUSIP G76279127) Reference is made to the Notice of Redemption (as defined below) under which Roivant Sciences Ltd. (the “Company”) committed to inform registered holders of the Company’s Warrants (as defined below) of the following infor |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2023 Roivant Sciences Ltd. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registr |
|
| August 14, 2023 |
Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update • RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses • First patient has been dosed in the TAHOE study, a global Phase 2 |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 Roivant Sciences Ltd. |
|
| August 7, 2023 |
Dear Roivant Shareholders, When I wrote our shareholder letter last year, we had an uncertain year ahead: it was early in the VTAMA launch, Immunovant had initiated its Phase 3 trial for batoclimab in myasthenia gravis just that month, and we had only recently announced the launch of Priovant to study brepocitinib. |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2023 Roivant Sciences Ltd. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 Roivant Sciences Ltd. |
|
| August 2, 2023 |
Roivant Announces Redemption of Outstanding Warrants Exhibit 99.1 Roivant Announces Redemption of Outstanding Warrants BASEL, Switzerland and LONDON and NEW YORK and BOSTON, August 2, 2023 (GLOBE NEWSWIRE) – Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) to |
|
| August 2, 2023 |
NOTICE OF REDEMPTION OF PUBLIC WARRANTS (CUSIP G76279119) AND PRIVATE WARRANTS (CUSIP G76279127) Exhibit 99.2 August 2, 2023 NOTICE OF REDEMPTION OF PUBLIC WARRANTS (CUSIP G76279119) AND PRIVATE WARRANTS (CUSIP G76279127) Dear Warrant Holder, Roivant Sciences Ltd. (the “Company”) hereby gives notice that it is redeeming, at 5:00 p.m. New York City Time on September 1, 2023 (the “Redemption Date”), all of the Company’s outstanding public warrants (the “Public Warrants”) and private warrants (t |
|
| July 31, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| June 29, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) ROIVANT SCIENCES LTD. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2)(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Equity Common shares, par value |
|
| June 29, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 As filed with the Securities and Exchange Commission on June 28, 2023 Registration No. |
|
| June 28, 2023 |
Exhibit 99.1 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update • RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses • A Phase 2 study of RVT-3101 in Crohn’s disease h |
|
| June 28, 2023 |
List of Subsidiaries of Roivant Sciences Ltd. EXHIBIT 21.1 List of Subsidiaries of Roivant Sciences Ltd. * The names of certain other subsidiaries of Roivant Sciences Ltd. are omitted because, considered in the aggregate, they would not constitute a “significant subsidiary.” Company Jurisdiction of Incorporation or Formation Affivant Sciences GmbH Switzerland Affivant Sciences Ltd. Bermuda Affivant Sciences, Inc. United States – Delaware Cova |
|
| June 28, 2023 |
Exhibit 10.44 Roivant Sciences Ltd. Restricted Stock Unit Award Grant Notice (2021 Equity Incentive Plan) Roivant Sciences Ltd. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the Participant a Restricted Stock Unit Award (the “RSU Award”) of the number of Restricted Stock Units (each an “RSU”, and together, the “RSUs”) as set forth below. Each RSU is an |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40782 ROIVANT SCIENCES |
|
| June 28, 2023 |
Amended & Restated Roivant Sciences Ltd. Employee Stock Purchase Plan Exhibit 10.27 ROIVANT SCIENCES LTD. EMPLOYEE STOCK PURCHASE PLAN (as amended on March 27, 2023) Section 1. Purpose. This Roivant Sciences Ltd. Employee Stock Purchase Plan (the “Plan”) is intended to provide employees of the Company and its Participating Subsidiaries with an opportunity to acquire a proprietary interest in the Company through the purchase of Shares. The Plan is intended to qualify |
|
| June 28, 2023 |
Exhibit 10.41 ROIVANT SCIENCES LTD. 2015 EQUITY INCENTIVE PLAN PERFORMANCE OPTION GRANT NOTICE Optionholder: [NAME] (the “Optionholder”) Company: Roivant Sciences Ltd., a Bermuda exempted limited company (the “Company”) Plan: Roivant Sciences Ltd. 2015 Equity Incentive Plan (as amended, the “Plan”) Notice: The Optionholder has been granted an option to purchase the number of Common Shares set fort |
|
| June 28, 2023 |
Exhibit 10.40 Roivant Sciences Ltd. Restricted Stock Unit Award Grant Notice (2015 Equity Incentive Plan) Roivant Sciences Ltd. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants to RSU Holder a Restricted Stock Unit Award (the “RSU Award”) of the number of Restricted Stock Units (each an “RSU”, and together, the “RSUs”) as set forth below. Each RSU is an oblig |
|
| June 28, 2023 |
Exhibit 10.39 Roivant Sciences Ltd. Stock Option Grant Notice (Amended and Restated 2015 Equity Incentive Plan) Roivant Sciences Ltd. (the “Company”), pursuant to its Amended and Restated 2015 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of common shares of the Company (the “Common Shares”) set forth below. This option is subject to all of the |
|
| June 28, 2023 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 31, 2023, Roivant Sciences Ltd. (the “Company,” “Roivant” or “we”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) common shares and (2) warrants. The following description |
|
| June 28, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2023 Roivant Sciences Ltd. |
|
| June 28, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2023 Roivant Sciences Ltd. |
|
| June 28, 2023 |
Exhibit 10.42 ROIVANT SCIENCES LTD. 2015 EQUITY INCENTIVE PLAN CAPPED VALUE APPRECIATION RIGHT AWARD GRANT NOTICE1 Participant: [NAME] (the “Participant”) Company: Roivant Sciences Ltd., a Bermuda exempted limited company (the “Company”) Plan: Roivant Sciences Ltd. 2015 Equity Incentive Plan (as amended, the “Plan”) Notice: The Participant has been granted an award of Capped Value Appreciation Rig |
|
| June 28, 2023 |
SEPARATION AND MUTUAL RELEASE AGREEMENT Exhibit 10.45 SEPARATION AND MUTUAL RELEASE AGREEMENT This SEPARATION AND MUTUAL RELEASE AGREEMENT (this “Agreement”) is entered into as of February 20, 2023, by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”) and Vivek Ramaswamy (the “Employee”). The Company and the Employee are collectively referred to herein as the “Parties” or individually referred to as a “Party”. C |
|
| June 28, 2023 |
Form of Stock Option Grant Notice under the Roivant Sciences Ltd. 2021 Equity Incentive Plan Exhibit 10.43 Roivant Sciences Ltd. Stock Option Grant Notice (2021 Equity Incentive Plan) Roivant Sciences Ltd. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the Participant an option to purchase the number of common shares of the Company (each, a “Common Share”) as set forth below. This option is subject to all of the terms and conditions as set forth |
|
| June 28, 2023 |
Exhibit 99.1 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update • RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses • A Phase 2 study of RVT-3101 in Crohn’s disease h |
|
| June 26, 2023 |
ROIV / Roivant Sciences Ltd / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Roivant Sciences Ltd. (Name of Issuer) Common shares, $0.0000000341740141 par value per share (Title of Class of Securities) G7 |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2023 Roivant Sciences Ltd. |
|
| June 22, 2023 |
Exhibit 99.1 Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period • This is the first-ever long-duration data reported for an anti-TL1A antibody • At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical |
|
| May 16, 2023 |
Exhibit 99.1 Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old - ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10th consecutive positive Phase 3 st |
|
| May 16, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2023 Roivant Sciences Ltd. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2023 Roivant Sciences Ltd. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 Roivant Sciences Ltd. |
|
| March 15, 2023 |
EX-99.1 2 brhc10049821ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old - 46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2023 Roivant Sciences Ltd. |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2023 Roivant Sciences Ltd. |
|
| February 14, 2023 |
ROIV / Roivant Sciences Ltd / SB INVESTMENT ADVISERS (UK) LTD - SC 13G/A Passive Investment SC 13G/A 1 d430675dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Roivant Sciences Ltd. (Name of Issuer) Common Shares (Title of Class of Se |
|
| February 14, 2023 |
ROIV / Roivant Sciences Ltd / QVT Financial LP - SC 13G/A Passive Investment SC 13G/A 1 d441940dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Roivant Sciences Ltd. (Name of Issuer) Common shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St |
|
| February 14, 2023 |
ROIV / Roivant Sciences Ltd / Dexcel Pharma Technologies Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm236181-1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Roivant Sciences Ltd. (Name of Issuer) Common shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this |
|
| February 14, 2023 |
ROIV / Roivant Sciences Ltd / Ramaswamy Vivek - SC 13G/A Passive Investment SC 13G/A 1 ny20007498x1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Roivant Sciences Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) G76279 101 (CUSIP Number) 12/31/2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 13, 2023 |
Exhibit 99.1 Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update • $9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launch • VTAMA payor coverage significantly expanded, with 57% of commercial live |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2023 Roivant Sciences Ltd. |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Reg |
|
| February 13, 2023 |
Investor Rights Agreement dated as of November 21, 2022 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. INVESTOR RIGHTS AGREEMENT THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of November 21, 2022 |
|
| February 13, 2023 |
License and Collaboration Agreement dated as of November 21, 2022 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AND COLLABORATION AGREEMENT by and between PFIZER INC. and [***] DATED AS OF NOVEMBER 21, 2022 TABL |
|
| February 7, 2023 |
Exhibit 1.1 ROIVANT SCIENCES LTD. 26,666,666 Common Shares (par value $0.0000000341740141 per share) Underwriting Agreement February 2, 2023 Goldman Sachs & Co. LLC SVB Securities LLC Cowen and Company, LLC Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, |
|
| February 7, 2023 |
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares Exhibit 99.1 Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares February 2, 2023 at 9:15 PM EST BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) – Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share. All o |
|
| February 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2023 Roivant Sciences Ltd. |
|
| February 6, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267503 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED OCTOBER 3, 2022) 26,666,666 Common Shares ROIVANT SCIENCES LTD. We are offering 26,666,666 common shares in this offering. Our common shares are listed on the Nasdaq Global Market under the trading symbol “ROIV.” On February 2, 2023, the last reported sale price of our common |
|
| February 3, 2023 |
EX-99.1 2 d398769dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares, par value $0.0000000341740141 per share, of Roivant Sciences Ltd. (this “Agreement”), |
|
| February 3, 2023 |
ROIV / Roivant Sciences Ltd / Sumitomo Chemical Co., Ltd. - SC 13G/A Passive Investment SC 13G/A 1 d398769dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Roivant Sciences Ltd. (Name of Issuer) Common Shares, par value $0.0000000341740141 per share (Title of Class of Securities) G76279101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta |
|
| February 1, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267503 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying pr |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2023 Roivant Sciences Ltd. |
|
| January 4, 2023 |
Exhibit 99.1 Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations • RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested • |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2023 Roivant Sciences Ltd. |
|
| December 1, 2022 |
Exhibit 99.1 Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases • Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis • RVT-3101 is currently being e |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2022 Roivant Sciences Ltd. |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2022 Roivant Sciences Ltd. |
|
| November 14, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. DATED 25th July 2022 GLAXOSMITHKLINE TRADING SERVICES LIMITED -and- DERMAVANT SCIENCES GMBH PARTIAL TERMINA |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Re |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 Roivant Sciences Ltd. |
|
| November 14, 2022 |
ROIVANT SCIENCES LTD. Selected Balance Sheet Data (unaudited, in thousands) Exhibit 99.1 Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update • Expected cash runway extended into the second half of calendar year 2025 • First major PBM/payer contract signed for VTAMA, effective October 1 • Over 54,000 VTAMA prescriptions written by approximately 6,400 prescribers since launch show strong demand, with fiscal |
|
| November 14, 2022 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”) HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Master Commercial Manufacturing and Supply Agreement between DERMAVANT SCIENCES GmbH Viaduktstrasse 8 4051 |
|
| November 10, 2022 |
EX-1.1 2 ny20005775x4ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 ROIVANT SCIENCES LTD. 30,000,000 Common Shares (par value $0.0000000341740141 per share) Underwriting Agreement November 8, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Roivant Sciences Ltd., a Bermuda exempted limited company (the “Company”), proposes to issue and sell to the several underwriters named |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 Roivant Sciences Ltd. |
|
| November 10, 2022 |
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering Exhibit 99.1 Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, November 8, 2022 – Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the pricing of its primary and secondary public offering of 30,000,000 com |
|
| November 9, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267503 PROSPECTUS SUPPLEMENT (TO PROSPECTUSES DATED OCTOBER 3, 2022) $150,000,000 20,000,000 Common Shares Being Offered by Roivant 10,000,000 Common Shares Being Offered by Selling Shareholders ROIVANT SCIENCES LTD. This is an offering of 30,000,000 common shares. We are offering 20,000,000 of the common shares in this offe |
|
| November 8, 2022 |
SUBJECT TO COMPLETION, DATED NOVEMBER 8, 2022 TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2022 Roivant Sciences Ltd. |
|
| November 7, 2022 |
Roivant Sciences Announces Proposed Public Equity Offering Exhibit 99.1 Roivant Sciences Announces Proposed Public Equity Offering BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, November 7, 2022 – Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roiv |
|
| October 3, 2022 |
Up to 566,982,174 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-267503 PROSPECTUS ? Up to 566,982,174 Common Shares The securityholders named in this prospectus or their permitted transferees (the ?Holders?) may offer and sell from time to time up to 566,982,174 common shares, par value $0.0000000341740141 per share (the ?Common Shares?). The Holders may offer, sell or distribute all or a |
|
| October 3, 2022 |
424B5 1 ny20005291x5424b5.htm 424B5 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267503 PROSPECTUS Up to $1,000,000,000 Common Shares Preference Shares Debt Securities Warrants Units From time to time, we may offer and sell up to an aggregate amount of $1.0 billion of any combination of the securities described in this prospectus, either individually or in combination, |
|
| October 3, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-267503 PROSPECTUS Up to $400,000,000 ? Common Shares We have entered into a sales agreement (the ?Sales Agreement?), with Cowen and Company, LLC (?Cowen?), relating to our common shares, par value $0.0000000341740141 per share (the ?Common Shares?), offered by this prospectus. In accordance with the terms of the Sales Agreemen |
|
| September 29, 2022 |
As filed with the Securities and Exchange Commission on September 29, 2022 As filed with the Securities and Exchange Commission on September 29, 2022 Registration No. |
|
| September 29, 2022 |
As filed with the Securities and Exchange Commission on September 29, 2022 As filed with the Securities and Exchange Commission on September 29, 2022 Registration No. |
|
| September 29, 2022 |
As filed with the Securities and Exchange Commission on September 29, 2022 As filed with the Securities and Exchange Commission on September 29, 2022 Registration No. |
|
| September 28, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 28, 2022 Roivant Sciences Ltd. |
|
| September 28, 2022 |
Exhibit 99.2 |
